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Context: Derangement of 11-b hydroxysteroid dehydrogenase type 1 and type 2 (11b-HSD1 and
11b-HSD2), which regulate intracellular cortisol production, has been suggested in both type 2 diabetes
(T2D) and chronic kidney disease (CKD). However, activity of 11b-HSD enzymes in patients with
T2D and CKD has never been assessed.
Objectives: To compare 11b-HSD activities between patients with T2D and healthy controls, and
assess whether in T2D, renal function is associated with 11b-HSD activities.
Design: Cross-sectional analysis in the Diabetes and Lifestyle Cohort Twente (DIALECT-1).
Setting: Referral center for T2D.
Patients: Patient with T2D [n = 373, age 646 9 years, 58%men, 26% of patients estimated glomerular
filtration rate (eGFR),60mL/min$1.73m2] and healthy controls (n = 275, age 536 11 years, 48%men).
Mean Outcome Measure: We measured cortisol, cortisone, and metabolites [tetrahydrocortisol
(THF), allo-THF (aTHF), and tetrahydrocortisone (THE)] in 24-hour urine samples. Whole body
11b-HSD and 11b-HSD2 activities were calculated as the urinary (THF + aTHF)/THE and cortisol/
cortisone ratios, respectively.
Results: Patients with T2D had a higher (THF + aTHF)/THE ratio [1.02 (0.84 to 1.27) vs 0.94 (0.79 to
1.0), P , 0.001] and cortisol/cortisone ratio [0.70 (0.58 to 0.83) vs 0.63 (0.54 to 0.74), P , 0.001] than
healthy controls. In T2D, lower eGFRwas associated with a higher (THF + aTHF)/THE ratio (b =20.35,
P , 0.001), and a higher cortisol/cortisone ratio (b = 20.16, P = 0.001).
Conclusions: In this real-life secondary care setting of patients with T2D, 11b-HSD enzymes activities
were shifted to higher intracellular cortisol production in T2D, whichwas further aggravated in patients
with CKD. Prospective analyses are warranted to investigate causality of these associations.
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
Abbreviations: 11b-HSD, 11-b hydroxysteroid dehydrogenase; aTHF, allo-tetrahydrocortisol; BMI, body mass index; CKD, chronic
kidney disease; DIALECT-1, Diabetes and Lifestyle Cohort Twente; eGFR, estimated glomerular filtration rate; MR, mineralo-
corticoid receptor; T2D, type 2 diabetes; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
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Metabolic similarities between patients with type 2 diabetes (T2D) and patients with
hypercortisolism (Cushing syndrome or glucocorticoid treatment) have given rise to the
hypothesis that relative hypercortisolism might occur in T2D [1]. Although overt hyper-
cortisolism is not typical in T2D, intracellular cortisol exposure is potentially increased
through upregulation of 11-b hydroxysteroid dehydrogenase type 1 (11b-HSD1), which re-
generates inactive cortisone to active cortisol in the liver and in adipose tissue, or down-
regulation of 11-b hydroxysteroid dehydrogenase type 2 (11b-HSD2), which reduces active
cortisol to inactive cortisone (Fig. 1). Sporadic studies have found signs that 11b-HSD ac-
tivities are shifted toward higher intracellular cortisol production in T2D, compared with
non-T2D subjects [2–4], although results are conflicting [5]. In patients with chronic kid-
ney disease (CKD), similar shifts in 11b-HSD activities have been suggested [6, 7]. However,
11b-HSD activities in patients with T2D with renal function impairment have never been
formally investigated.
Interest in 11b-HSD pathways has recently been refueled after the development of several
compounds that inhibit 11b-HSD1. Phase II preclinical trials with such agents have shown
improved glycemic control, lipid profile, and blood pressure, and even demonstrated modest
weight loss [8]. However, effects on each separate component of the metabolic syndrome were
relatively small. If 11b-HSD1 activity is highest in T2D with renal function impairment, this
couldmean that pharmacological 11b-HSD1 inhibition could be a promising treatment option
specifically for these patients.
In the current study, we therefore quantified total urinary excretion of cortisol, cortisone,
and their metabolites [tetrahydrocortisol (THF), allo-THF (aTHF), tetrahydrocortisone
(THE)] with the aim of estimating (1) whether 11b-HSD activities differ between patients
with T2D and healthy controls, and (2) to investigate whether there is an association
between estimated glomerular filtration rate (eGFR) and 11b-HSD activities in patients
with T2D.
1. Subjects and Methods
We performed a cross-sectional analysis in baseline data from the Diabetes and Lifestyle
Cohort Twente-1 (DIALECT-1). The study design was described in detail elsewhere [9]. The
study was approved by the local institutional review board (METC-Twente, registration
number: NL57219.044.16) and the institutional review board in the University Medical
Centre Groningen (METC-Groningen registration number: 1009.68020), and is registered in
the Netherlands Trial Register (NTR trial code 5855). The study was performed according to
the guidelines of good clinical practice and the Declaration of Helsinki.
A. Participants
All patients with T2D treated in the outpatient clinic of our hospital, aged 18+ years, were
eligible for the study. Exclusion criteria were inability to understand the informed consent
procedure, insufficient command of the Dutch language, or dialysis dependency. As a control
group reflecting the general population, we included 275 healthy subjects who participated
Figure 1. Effect of 11b-HSD activities on intracellular cortisol levels. 11b-HSD1 increases
cortisol levels by regenerating inactive cortisone to active cortisol. 11b-HSD2 decreases
cortisol levels by reducing active cortisol to inactive cortisone.
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in a screening program before kidney donation in the University Medical Centre Groningen.
None of the healthy controls had a history of diabetes, cardiovascular events, or kidney disease.
Hypertension, if present, was treated with a maximum of one class of antihypertensive drugs.
B. Study Procedures
Eligible patients were selected from the electronic patient file. At the clinic, sociodemographic
characteristics, medical history, lifestyle behaviors, and current medications were recorded.
Height, weight, waist, and hip circumference were measured. Body mass index (BMI) was
calculated as weight divided by height squared (kg/m2), and body surface area was estimated
by applying the universally adopted formula of DuBois. Blood pressure was measured in a
supine position by an automated device (Dinamap®; GE Medical Systems, Milwaukee, WI)
for 15 minutes with a 1-minute interval. The mean systolic and diastolic pressure of the final
three measurements was used for further analysis.
Blood was drawn from venepuncture for routine laboratory measurements. Serum
concentration of C-reactive protein was measured routinely using immunoassay. From a
24-hour urine collection the following parameters are measured: sodium, potassium,
creatinine, calcium, phosphate, and uric acid excretion. For the proper collection of the
24-hour urine sample, patients were instructed to dispose the first morning void urine, and
thereafter collect all urine in the provided canister until the first morning void urine of
the next day. In between voids, they were instructed to store the canister in a dark cool
place, preferably in a refrigerator. Samples of blood and 24-hour urine were stored for
later analysis.
C. Cortisol Measurements
Urinary cortisol, cortisone, THF, aTHF, and THE concentrations in 24-hour urine samples
were measured using a validated high-performance liquid chromatography tandem mass
spectrometry assay as previously described [10]. For all components, stable isotope labeled
internal standards were added and the mixtures were incubated with an enzyme solution
consisting of sulfatases and b-glucuronidases (Suc d’Helix Pomatia, Pall Biopharmaceuticals,
PortWashington, NY), to ensure hydrolysis of cortisol and themetabolites from their sulfated
and glucuronidated forms. In contrast to the more generally applied urinary free cortisol
measurement, this method measures total cortisol and its metabolites. Subsequently, the
analytes were extracted using a Supported Liquid Extraction technique. Finally, separation
and detection were performed by use of a CSH Phenyl-Hexyl column (particle size 1.7 mm,
2.1mm internal diameter by 100mm;Waters, Milford,MA) and a XEVOTQ-s® tandemmass
spectrometer operated in negative electrospray ionizationmode (Waters), respectively. Intra-
and interassay variation coefficients were ,5.7% and ,9.8%, respectively. Prednisone and
prednisolone were chromatographically separated from cortisol and its metabolites and
therefore did not interfere. Total 24-hour urinary excretions were calculated by multiplying
the concentrations by 24-hour urinary volume.
The urinary ratios of (THF + aTHF)/THE and cortisol/cortisone are widely used to assess
enzyme activity of 11b-HSD1 and 11b-HSD2. The urinary cortisol/cortisone ratio is con-
sidered to reflect activity of 11b-HSD2, whereas the urinary (THF + aTHF)/THE ratio is
considered as an overall measure of whole body 11b-HSD activity [11–13].
D. Data Analysis and Statistics
Statistical analyses were performed using Statistical Package for the Social Sciences (IBM,
Chicago, IL), version 22.0. Normality of data was assessed by visually inspecting the fre-
quency histograms. Normally distributed data are shown as mean 6 SD, skewed data are
shown asmedian (interquartile range), and nominal data as number of patients (percentage).
Differences between patients with T2D and healthy controls were tested using linear
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regression analyses, unadjusted and while adjusting for potential confounders such as
gender, age, and BMI.
Using R software, the univariate associations between eGFR and the (THF + aTHF)/THE
and cortisol/cortisone ratios were assessed with generalized additive models (mgcv
package; The R-Foundation for Statistical Computing, Vienna, Austria) as described
previously [14]. The model effect and nonlinearity were tested with the use of two-sided
Wald tests. P-nonlinearity values were calculated by comparing restricted cubic spline
terms to linear models.
To identify possible confounders, we determined the associations between clinical pa-
rameters and the (THF +aTHF)/THE and cortisol/cortisone ratios using linear regression
analyses. Then we performed multivariate linear regression to determine the association
between eGFR and the (THF + aTHF)/THE and cortisol/cortisone ratios, while adjusting for
common confounders and for parameters with a P , 0.15 in univariate analysis. To test for
gender differences, we also performed the analyses for men and women separately.
2. Results
Data on urinary cortisol excretion were available in 373 patients of DIALECT-1 and in 275
healthy controls (Table 1). In patients with T2D, the mean age was 646 9 years, the majority
were men (58%), and mean BMI was 32.86 6.0 kg/m2. The median diabetes duration was 11
(7 to 18) years, metformin was used by 74% of patients (n = 277), and 67% (n = 250) of patients
were on insulin. The majority of patients with T2D had one or more microvascular compli-
cations (70%), with nephropathy being the most prevalent (49%), and macrovascular compli-
cations were present in 39% of patients. Impaired renal function (eGFR, 60 mL/min$1.73 m2)
was present in 96 (26%) patients. In the healthy controls, therewere fewermen (48%;P = 0.008),
participants were younger (536 11; P, 0.001), had a lower BMI (25.96 3.5; P, 0.001), and a
higher eGFR (91 6 24 vs 78 6 24 mL/min$1.73 m2; P , 0.001), as compared with patients
with T2D.
A. Total 24-Hour Urinary Excretion of Cortisol and Cortisol Metabolites in Patients With T2D
and Healthy Controls
Urinary excretion of cortisol and its metabolites in patients with T2D and healthy controls is
demonstrated in Table 1. The median urinary excretion of cortisol and cortisone was lower in
T2D than in healthy controls [cortisol 274 (204 to 400) vs 332 (244 to 445) nmol/24 hours; P,
0.001; cortisone 408 (308 to 549) vs 526 (418 to 648) nmol/24 hours; P, 0.001]. However, the
ratio of cortisol/cortisone was higher in patients with T2D [1.02 (0.84 to 1.27) vs 0.94 (0.79 to
1.00), P , 0.001], also when adjusting for age, gender, and BMI. In addition, there was no
difference in urinary excretion of THF, aTHF, THE, and summated cortisol and metabolites
between patients with T2D and healthy controls. The (THF + aTHF)/THE ratio, however, was
again higher in T2D [0.70 (0.58 to 0.83) vs 0.63 (0.54 to 0.74);P, 0.001], also after adjustment
for confounders. Differences in both ratios between patients with T2D and healthy controls
were similar in men and women (data not shown).
B. Associations Between eGFR and the (THF+aTHF)/THE Ratio and Cortisol/Cortisone
Ratios in T2D
In patients with T2D, there was an inverse linear association between eGFR and the log
transformed (THF + aTHF)/THE ratio (b =20.35, P, 0.001, P nonlinearity = 0.14; Fig. 2A).
In addition, eGFR was also inversely associated with the cortisol/cortisone ratio (b = 20.16,
P = 0.001, P nonlinearity = 0.27; Fig. 2B).
As secondary analyses, we also investigated the associations of the (THF + aTHF)/
THE and the cortisol/cortisone ratios with clinical characteristics (Table 2). We found
that the (THF + aTHF)/THE ratio was associated with gender (b = 20.14, P = 0.006), age
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(b = 0.16, P = 0.002), systolic blood pressure (b = 20.13, P = 0.01), diastolic blood pressure
(b = 20.14, P = 0.008), presence of coronary heart disease (b = 0.16, P = 0.002), b blocker
use (b = 0.14, P = 0.005), loop diuretic use (b = 0.13, P = 0.01), and plasma LDL cholesterol
(b = 20.15, P = 0.006). Insulin use was not significantly associated with the (THF + aTHF)/
THE ratio, and in insulin users there was no association between cumulative daily insulin
dosage and the (THF + aTHF)/THE ratio. Of note, adjustment for factors associated with the
(THF+aTHF)/THE ratio did not markedly influence the association between eGFR and (THF +
aTHF)/THE (fully adjusted model: b = 20.37, P , 0.001; Table 3). The association between
eGFR and the (THF + aTHF)/THE ratio was similar for men and women (data not shown).
In parallel, the cortisol/cortisone ratio was associated with the presence of cerebrovascular
disease (b = 0.17, P = 0.001), loop diuretic use (b = 0.10, P = 0.05), and LN serum C-reactive
protein (b = 0.23, P , 0.001). Plasma aldosterone concentration and 24-hour urinary al-
dosterone excretion were not associated with the cortisol/cortisone ratio. Again, the asso-
ciation between eGFR and the cortisol/cortisone ratio was unaltered by adjustment
for possible confounders (fully adjusted model: b =20.14, P = 0.03; Table 4). Additionally, the
b of the association between eGFR and the cortisol/cortisone ratio was similar in men and
women, although the association only statistically significant in men (fully adjusted models:
b = 20.17, P = 0.05 for men, b = 20.15, P = 0.14 for women).
Table 1. Patients Characteristics and Urinary Excretion of Cortisol Metabolites
Healthy Controls T2D Standardized b
Patient Characteristics n = 275 n = 373 Model 1 Model 2 Model 3
Men, n (%) 132 (48) 215 (58) 20.10**
Age, y 53 6 11 64 6 9 0.43***
BMI, kg/m2 25.9 6 3.5 32.8 6 6.0 0.53*** 0.58***
Systolic blood pressure, mm Hg 125 6 14 136 6 16 0.33*** 0.26*** 0.22***
Diastolic blood pressure, mm Hg 76 6 9 74 6 10 0.06 20.02 0.002
HbA1c, mmol/mol 38 6 4 57 6 12 0.71*** 0.70*** 0.70***
Nonfasting glucose, mmol/L 5.4 6 0.7 9.5 6 3.4 0.60*** 0.58*** 0.58***
Total cholesterol, mmol/L 5.4 6 1.1 4.0 6 0.9 20.58*** 20.60*** 20.59***
LDL cholesterol, mmol/L 2.0 6 0.7
Triglycerides, mmol/L 1.4 6 0.8 1.9 6 1.2 0.24*** 0.26*** 0.17**
HDL cholesterol, mmol/L 1.1 6 0.3
eGFR, mL/min$1.73 m2 91 6 14 78 6 24 20.29*** 20.05 20.009
eGFR ,60 mL/min$1.73 m2, n (%) 4 (1%) 96 (26)
eGFR ,30 mL/min$1.73 m2, n (%) 0 (0) 14 (3)
Increased albuminuria, n (%) 15 (6) 136 (31) 0.30*** 0.25*** 0.24***
Microvascular disease, n (%) NA 260 (70)
Macrovascular disease, n (%) NA 144 (39)
Metformin use, n (%) NA 277 (74)
Sulfonylurea use, n (%) NA 87 (23)
Insulin use, n (%) NA 250 (67)
Urinary excretion of cortisol metabolites
Urinary cortisol excretion, nmol/24 h 332 (244–445) 274 (204–400) 20.15*** 20.15** 20.16**
Urinary cortisone excretion, nmol/24 h 526 (418–648) 408 (308–549) 20.25*** 20.24*** 20.24***
Urinary THF excretion, mmol/24 h 6.9 (5.1–9.3) 7.0 (5.3–9.5) 0.02 20.005 20.11*
Urinary LNaTHF excretion,mmol/24 h 4.2 (2.6–6.5) 4.8 (2.7–7.5) 0.07 0.05 20.07
Urinary THE excretion, mmol/24 h 12.5 (8.5–16.8) 11.5 (8.1–15.3) 20.06 20.03 20.16**
Summated urinary cortisol and
metabolites excretion, mmol/24 h
24.6 (17.4–33.7) 24.3 (18.5–32.3) 20.02 20.01 20.15**
(THF+aTHF)/THE, mmol/mmol 0.94 (0.79–1.0) 1.02 (0.84–1.27) 0.19*** 0.12** 0.11*
Cortisol/cortisone, nmol/nmol 0.63 (0.54–0.74) 0.70 (0.58–0.83) 0.15*** 0.14** 0.14*
Differences between groups were tested via univariable and multivariable linear regression analyses of which
standardized bs are presented (*P, 0.05, **P, 0.01, ***P, 0.001). Model 1 is a crude model. Model 2 was adjusted
for age and gender. Model 3 was adjusted as for Model 2 and for BMI.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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3. Discussion
To our knowledge this is the first study on 11b-HSD activities in patients with T2D with a
large subgroup of patients with renal function impairment. We found that both the uri-
nary (THF + aTHF)/THE and cortisol/cortisone ratios were higher in patients with T2D as
compared with healthy controls. Additionally, lower renal function was associated with
higher urinary (THF + aTHF)/THE and cortisol/cortisone ratios in patients with T2D. These
findings suggest that in T2D, intracellular cortisol exposure is increased, and that in diabetic
kidney disease, there is even further derangement of 11b-HSD activity toward intracellular
cortisol production.
We measured urinary excretion of cortisol and its metabolites using high-performance
liquid chromatography tandem mass spectrometry, after hydrolysis from their sulfated and
glucuronidated forms. Because in other literature the hydrolysis step usually is not per-
formed, we report a higher excretion of cortisol and its metabolites, and therefore direct
comparison of our data with previous literature is not possible.
In line with our findings, prior observations in small groups of patients with T2D
reported a shift toward higher intracellular cortisol production in patients with T2D as
compared with healthy controls [2, 3]. Studies assessing solely 11b-HSD1 activity, by
measuring the conversion of labeled cortisol to cortisone, reported higher activity of 11b-
HSD1 in patients with T2D than in overweight/obese controls without T2D [2, 3]. On the
other hand, Valsamakis et al. [5] found no statistically significant difference in the urinary
(THF + aTHF)/THE and cortisol/cortisone ratios between patients with T2D and controls. It
should be noted that in the latter study, patients were in an earlier disease stage than in our
study; patients were younger, there were no insulin users, and patients with renal function
impairment were excluded, whereas in our study, the median diabetes duration was 11 (7 to
18) years, and approximately two-thirds of patients used insulin. Lavery et al. [4] previously
reported an increased frequency of short alleles of the 11b-HSD2 gene in T1D, suggesting
reduced activity of 11b-HSD2 in diabetes, however, without measurement of in vivo
11b-HSD2 activity. Our larger study adds to these findings by illustrating that in established
Figure 2. Continuous associations of eGFR with (A) the log transformed urinary (THF+aTHF)/
THE and (B) the cortisol/cortisone ratios in patients with T2D (n = 373). Continuous associations
were modeled via generalized additive models. Shaded areas represent the corresponding
95% CIs. The histograms illustrate distributions of eGFR in patients with T2D. For the
association between eGFR and natural logarithm (THF+aTHF)/THE, P-nonlinearity was
0.14, and the b was 20.35 (P , 0.001). In case of the urinary cortisol/cortisone ratio, the
P-nonlinearity was 0.27, and the b was 20.16 (P = 0.001).
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T2D in a real-life setting, both total body 11b-HSD activity and 11b-HSD2 activity are shifted
toward higher intracellular cortisol exposure in T2D, independent of age, gender, and BMI.
Although the mechanisms behind derangement of 11b-HSD activities in T2D is unknown,
Anderson et al. [15] previously described that metformin may increase whole body 11b-HSD1
activity, potentially diminishing other metabolic effects of metformin. Here we found a
nonstatistically significant trend toward lower 11b-HSD1 activity in patients on metformin.
However, it should be noted our population represents patients with long-standing T2D [11 (7
to 18) years], complicating direct comparison of results. Prospective research is needed to
further clarify the effects of metformin on 11b-HSD1 activity.
Table 2. Unadjusted Associations Between Clinical Parameters and the (THF + aTHF)/THE and
Cortisol/Cortisone Ratios in Patients With T2D
LN (THF + aTHF)/THE Cortisol/Cortisone
n = 374 Stand b P Value Stand b P Value
Patient characteristics
Women 20.14 0.006 20.01 0.83
Age, y 0.16 0.002 0.09 0.08
Duration of diabetes, y 0.07 0.20 0.02 0.64
BMI, kg/m2 ,0.01 0.98 0.04 0.43
Current smoker 20.02 0.66 0.10 0.06
Alcohol use (yes/no) 20.02 0.73 20.02 0.70
Systolic blood pressure, mm Hg 20.13 0.01 0.03 0.62
Diastolic blood pressure, mm Hg 20.14 0.008 0.00 0.95
Heart frequency, beats/min 20.08 0.13 0.10 0.06
Comorbidity
Microvascular disease 0.17 0.001 0.10 0.05
Retinopathy 0.03 0.58 0.02 0.74
Neuropathy 0.05 0.39 0.01 0.79
Nephropathy 0.12 0.02 0.10 0.07
Macrovascular disease 0.17 0.001 0.08 0.11
Coronary heart disease 0.16 0.002 0.00 0.96
Cerebrovascular disease 0.10 0.06 0.17 0.001
Peripheral artery disease 0.06 0.25 0.02 0.73
Pharmacological treatment
RAAS inhibition ,0.001 0.99 20.02 0.72
b-blocker 0.14 0.005 0.02 0.67
Calcium antagonist 0.05 0.30 0.02 0.69
Thiazide diuretics 0.02 0.73 20.05 0.36
Loop diuretics 0.13 0.01 0.10 0.05
Potassium saving diuretics 0.11 0.04 0.02 0.78
Metformin 20.08 0.13 0.02 0.77
Insulin 0.03 0.51 20.08 0.15
Cumulative insulin dosage, units/d 20.09 0.21 20.002 0.98
Serum values
Serum HbA1c, mmol/mol 20.10 0.06 0.05 0.36
Plasma total cholesterol, mmol/L 20.15 0.004 20.02 0.75
Plasma LDL cholesterol, mmol/L 20.15 0.006 0.04 0.48
Plasma HDL cholesterol 20.06 0.24 20.07 0.20
Plasma aldosterone concentration, pg/mL 0.08 0.17 0.07 0.22
LN serum CRP, mg/L 0.09 0.09 0.23 ,0.001
Urinary excretion
LN Urinary albumin excretion, mg/24 h 0.07 0.22 0.05 0.39
Urinary Cortisol/cortison, nmol/nmol 0.20 ,0.001
LN (THF + aTHF)/THE, mmol/mmol 0.20 ,0.001
Urinary aldosterone excretion, mg/24 h 0.02 0.72 20.04 0.45
Associations were tested using univariate linear regression of which standardized bs and P values are presented.
Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LN, natural
logarithm.
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In patients with T2D, we found that the urinary (THF + aTHF)/THE and cortisol/
cortisone ratios are inversely associated with eGFR. To our knowledge, the association
between 11b-HSD activity and eGFR in T2D has not been reported previously. Our finding
is supported by a previous study by Quinkler et al. [6], which demonstrated an inverse
association between creatinine clearance and the urinary (THF + aTHF)/THE and cortisol/
cortisone ratios in nondiabetic patients with renal function impairment. In line, Whitworth
et al. [16] reported an association between higher plasma creatinine and lower plasma
cortisone levels in nondiabetic patients with CKD, indicative of an association between
lower eGFR and lower 11b-HSD2 activity. The mechanism underlying the association
between lower renal function and altered 11b-HSD activities is unknown. In (diabetic)
CKD, there is neuroendocrinological derangement, with increased sympathetic activity,
illustrated by higher inflammatory markers, and higher cortisol and aldosterone levels in
CKD [17–20]. Possibly, in CKD, alteration of 11b-HSD activities is part of this neuroen-
docrinological derangement. Indeed, we found that a trend between higher C-reactive
protein and altered 11b-HSD activities, which is in line with previous research on 11b-HSD
activities in inflamed tissues [21, 22]. However, as of now it is unknown whether a higher
degree of inflammation leads to 11b-HSD dysregulation or vice versa. In case of the latter,
Table 3. AssociationBetweeneGFRand theUrinary (THF+aTHF)/THERatio inPatientsWithT2DAfter
Adjustments for Possible Confounders
LN (THF + aTHF)/THE
Stand b P Value
Model 1, eGFR, mL/min$1.73 m2 20.36 ,0.001
Model 2, eGFR, mL/min$1.73 m2 20.39 ,0.001
Model 3, eGFR, mL/min$1.73 m2 20.38 ,0.001
Model 4, eGFR, mL/min$1.73 m2 20.38 ,0.001
Model 5, eGFR, mL/min$1.73 m2 20.37 ,0.001
Model 6, eGFR, mL/min$1.73 m2 20.37 ,0.001
Associations were tested using multivariate linear regression of which standardized bs and P values are presented.
Model 1 was a crude model. Model 2 was adjusted for age and gender. Model 3 was adjusted for Model 2 + coronary
artery disease (no/yes), and cerebrovascular disease (no/yes). Model 4 was adjusted forModel 3 + BMI (kg/m2), alcohol
intake (none/any), and current smoking (no/yes). Model 5 was adjusted forModel 4 + systolic blood pressure (mmHg),
diastolic blood pressure (mm Hg), heart frequency (beats/min), and LDL cholesterol (mmol/L). Model 6 was adjusted
for Model 5 + b blocker use (no/yes), loop diuretic use (no/yes), potassium saving diuretic use (no/yes), and metformin
use (no/yes).
Abbreviation: LN, natural logarithm.
Table 4. Adjusted Associations Between Clinical Parameters and the Urinary Cortisol/Cortisone Ratio
in Patients With T2D
Cortisol/cortisone
Stand b P Value
Model 1, eGFR, mL/min$1.73 m2 20.17 0.001
Model 2, eGFR, mL/min$1.73 m2 20.17 0.007
Model 3, eGFR, mL/min$1.73 m2 20.14 0.02
Model 4, eGFR, mL/min$1.73 m2 20.14 0.03
Model 5, eGFR, mL/min$1.73 m2 20.16 0.01
Model 6, eGFR, mL/min$1.73 m2 20.14 0.03
Associations were tested using multivariate linear regression of which standardized bs and P values are presented.
Model 1 was a crude model. Model 2 was adjusted for age and gender. Model 3 was adjusted for Model 2 + cere-
brovascular disease (no/yes). Model 4 was adjusted for Model 3 + BMI (kg/m2), alcohol intake (none/any), and current
smoking (no/yes).Model 5 was adjusted forModel 4 + heart frequency (beats/min).Model 6 was adjusted forModel 5 +
loop diuretic use (no/yes) and insulin use (no/yes).
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altered 11b-HSD activities could be associated with inflammation-related complica-
tions commonly seen in CKD, such as insulin resistance, dyslipidemia, and hypertension
[23–25]. Additionally, altered cortisol handling may have consequences for clinical out-
comes in CKD, previously, Himmelfarb et al. [26] demonstrated that higher predialysis
serum cortisol levels were associated with higher rates of hospitalization and malnutrition.
It should be noted that in our cohort there were few patients with end-stage renal failure
(eGFR, 15mL/min$1.73m2). It would be interesting to investigate whether the association
between eGFR and 11b-HSD activities remains linear if the population would be expanded
with patients withmore severe impairment of renal function and patients approaching end-
stage renal failure.
Moreover, 11b-HSD2 inactivates cortisol in the intracellular space, thus avoiding cortisol
mediated mineralocorticoid receptor (MR) activation. Lower 11b-HSD2 activity in those
with renal function impairment suggests increased MR activation by cortisol. MR acti-
vation has been associated with a plethora of detrimental effects on target organs, such as
the kidneys, the heart, and the vasculature, which can be blocked by MR antagonism
[27–34]. Therefore, lower 11b-HSD2 activity in T2D could play an important role in the
development and course of diabetic nephropathy. However, it should be noted that in the
current study we found no association between 11b-HSD2 and markers of MR activation
such as plasma aldosterone concentration, urinary aldosterone excretion, blood pressure,
and hypokalemia, although such relations might well be disturbed by unstandardized
sodium intake and frequent use of antihypertensives interfering in the renin-angiotensin-
aldosterone system.
Our study has several strengths. First, this is the largest study to date on 11b-HSD
activities in patients with T2D and renal function impairment. Because previous assays for
measuring cortisol metabolites were difficult to perform in a large group of patients, little
data are available on the epidemiology of 11b-HSD activities. Second, the broad inclusion
criteria of DIALECT-1 allow us to study a group of real-world patients with T2D treated
in secondary care, with minimal inclusion bias. The primary limitation of the study is
the cross-sectional design, which does not allow conclusions on causality. Therefore, the
results of our study should be seen as predominantly hypothesis generating. In-depth
prospective studies are necessary to validate our findings. Furthermore, it should be noted
the urinary (THF + aTHF)/THE ratio is an indirect marker of whole body 11b-HSD enzyme
activity, and therefore should be interpreted with caution, because 11b-HSD activity might
differ between different tissues. Additionally, the (THF + aTHF)/THE ratio can only be
used to interpret 11b-HSD1 activity if the urinary cortisol/cortisone ratios are unaltered.
Therefore, additional studies are necessary to assess whether in T2D and CKD 11b-HSD1
activity specifically is altered similarly as 11b-HSD2 activity. Also, due to the fact that
blood was taken in a nonfasting state, data on fasting glucose and homeostatic model
assessment for insulin resistance were unavailable in DIALECT-1. Therefore, the asso-
ciation between 11b-HSD activities and insulin resistance could not be assessed directly.
Lastly, previously it has been demonstrated that higher urinary cortisol excretion is
associated with oxidative stress [35]. It would be interesting to investigate whether the
11b-HSD derangement in T2D and CKD we report here is also associated with markers of
oxidative damage; however, data on markers of oxidative stress were not available in
this study.
Our findings have several potential clinical implications. The shift toward higher in-
tracellular cortisol production by 11b-HSD enzymes in T2D with renal function impairment
could indicate that 11b-HSD1 inhibitors might have an increased beneficial effect in patients
with diabetic nephropathy. Additionally, the lower 11b-HSD2 activity in T2D and renal
function impairment might have implications for treatment with MR antagonists, especially
in diabetic nephropathy. Future prospective studies are necessary to validate our findings,
and assess the association between 11b-HSDs derangements and clinical adverse outcomes.
Additionally, future studies should be performed to evaluate whether alterations between
11b-HSD in T2D patients with CKD are similar to CKD patients without T2D.
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4. Conclusion
This is the largest study to date on 11b-HSD activities in a real-life secondary care setting of
patients with T2D. We found that activity of 11b-HSDs is shifted toward higher intracellular
cortisol production in T2D, and especially in those with T2D and renal function impairment.
This could have important implications for the use of both 11b-HSD1 inhibitors and MR
antagonists in T2D and renal function impairment.
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